Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Anifrolumab in Adults with Active Systemic Lupus Erythematosus
2014-004632-19Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Anifrolumab with Placebo (2 arms). Primary endpoint: Primary endpoint: SRI(4) response at Week 52. Started Jun 2015; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2014-004632-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004632-19.